Enochian Biosciences Inc received a notice terminating a License Agreement for their product candidate RENB-HV-01, which has been deprioritized, but they are considering their options. Their lead candidate is RENB-DC-11, a potential cancer vaccine for solid tumors, and they are also engaged in HIV research.